To enhance the benefit of fulvestrant and improve outcomes for individuals with ER-positive breast cancer, greater understanding of resistance mechanisms is required. A key issue is identification of patients with ER-positive disease who retain sensitivity to antiestrogen therapy after progression on tamoxifen and/or aromatase inhibitors
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer / Oakman C; Moretti E; Santarpia L; Di Leo A. - In: FUTURE ONCOLOGY. - ISSN 1744-8301. - ELETTRONICO. - (2011), pp. 173-186.
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer
MORETTI, ERICA;
2011
Abstract
To enhance the benefit of fulvestrant and improve outcomes for individuals with ER-positive breast cancer, greater understanding of resistance mechanisms is required. A key issue is identification of patients with ER-positive disease who retain sensitivity to antiestrogen therapy after progression on tamoxifen and/or aromatase inhibitors
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
